Oligomerix is a biotechnology company established in November 2006 with the primary objective of creating a unique platform technology for drug discovery and biomarker development targeting central nervous system (CNS) disorders such as AD. The company aims to utilize this platform to identify distinctive, drug-like small molecules that can obstruct the self-association of tau into toxic oligomers. The company has progressed its technologies through its equity investment, grants from NIH, and support from the Alzheimer’s Drug Discovery Foundation (ADDF). It has developed a robust business model centered around its core technologies and holds a strong intellectual property (IP) position.